Please assess the completion status of the following clinical trial:

Trial Title: A Survey on Efficacy and Safety in Patients With Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged 20 to \< 50 years~* Subjects with a chocolate cyst of the ovary measuring 3 cm in diameter on transvaginal ultrasonography at patient enrollment~* Subjects with a menstrual cycle of 25 to 38 days who ovulate and are confirmed to have normal menstruation at patient enrollment~Exclusion Criteria:~* Subjects who used GnRH agonists within 6 months before patient enrollment~* Subjects who utilized hormone preparations containing corpus luteum hormone or estrogen as an active ingredient, low-dose contraceptive pills, middle-dose contraceptive pills, testosterone derivatives, or herbal products indicated for endometriosis within 3 months before patient enrollment~* Subjects who received surgical treatment for endometriosis such as transvaginal alcohol fixation, laparotomy or laparoscopic surgery within 2 months before patient enrollment~* Subjects who are pregnant or may possibly be pregnant at patient enrollment~* Subjects who are in breast feeding at patient enrollment~* Subjects who are determined by the investigator/subinvestigator to be not suitable for the subjects of the survey because of other reasons~* Subjects with liver disorder or liver disease~* Subjects with known hypersensitivity to the active substance or to any of the excipients~* Subjects with known or suspected progestogen dependent neoplasms (e.g. meningioma)~* Subjects with undiagnosed vaginal bleeding~* Subjects with a past or current history of heart or kidney disease~* Subjects with porphyria~* Subjects with depression~* Subjects with abnormal liver function values caused by acute or chronic liver disease~* Subjects with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Dydrogesterone (Type: None): Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).